FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Status:
Terminated
Trial end date:
2018-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with
gastroenteropancreatic high-grade neuroendocrine carcinomas.
This is a prospective Phase II open-label trial, stratifying gastroenteropancreatic high
grade neuroendocrine carcinomas participants equally into two cohorts (first-line versus
beyond first-line).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute